Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity P Browne, D Chandraratna, C Angood, H Tremlett, C Baker, BV Taylor, ... Neurology 83 (11), 1022-1024, 2014 | 1528 | 2014 |
The prevalence of MS in the United States: a population-based estimate using health claims data MT Wallin, WJ Culpepper, JD Campbell, LM Nelson, A Langer-Gould, ... Neurology 92 (10), e1029-e1040, 2019 | 991 | 2019 |
Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis S Simpson Jr, B Taylor, L Blizzard, AL Ponsonby, F Pittas, H Tremlett, ... Annals of neurology 68 (2), 193-203, 2010 | 629 | 2010 |
The gut microbiome in human neurological disease: a review H Tremlett, KC Bauer, S Appel‐Cresswell, BB Finlay, E Waubant Annals of neurology 81 (3), 369-382, 2017 | 514 | 2017 |
Disability progression in multiple sclerosis is slower than previously reported H Tremlett, D Paty, V Devonshire Neurology 66 (2), 172-177, 2006 | 453 | 2006 |
New perspectives in the natural history of multiple sclerosis H Tremlett, Y Zhao, P Rieckmann, M Hutchinson Neurology 74 (24), 2004-2015, 2010 | 376 | 2010 |
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis A Shirani, Y Zhao, ME Karim, C Evans, E Kingwell, ML Van Der Kop, ... Jama 308 (3), 247-256, 2012 | 341 | 2012 |
Gut microbiota in early pediatric multiple sclerosis: a case− control study H Tremlett, DW Fadrosh, AA Faruqi, F Zhu, J Hart, S Roalstad, J Graves, ... European journal of neurology 23 (8), 1308-1321, 2016 | 331 | 2016 |
Relapses in multiple sclerosis are age-and time-dependent H Tremlett, Y Zhao, J Joseph, V Devonshire Journal of neurology, Neurosurgery & psychiatry 79 (12), 1368-1374, 2008 | 291 | 2008 |
Natural history of secondary-progressive multiple sclerosis H Tremlett, Y Zhao, V Devonshire Multiple Sclerosis Journal 14 (3), 314-324, 2008 | 276 | 2008 |
Interrupted therapy: stopping and switching of the β-interferons prescribed for MS HL Tremlett, J Oger Neurology 61 (4), 551-554, 2003 | 275 | 2003 |
Impact of multiple sclerosis relapses on progression diminishes with time H Tremlett, M Yousefi, V Devonshire, P Rieckmann, Y Zhao Neurology 73 (20), 1616-1623, 2009 | 266 | 2009 |
The natural history of secondary progressive multiple sclerosis M Koch, E Kingwell, P Rieckmann, H Tremlett Journal of Neurology, Neurosurgery & Psychiatry 81 (9), 1039-1043, 2010 | 242 | 2010 |
The natural history of primary progressive multiple sclerosis M Koch, E Kingwell, P Rieckmann, H Tremlett Neurology 73 (23), 1996-2002, 2009 | 230 | 2009 |
Health-related quality of life in multiple sclerosis: direct and indirect effects of comorbidity LI Berrigan, JD Fisk, SB Patten, H Tremlett, C Wolfson, S Warren, KM Fiest, ... Neurology 86 (15), 1417-1424, 2016 | 228 | 2016 |
Longitudinal follow-up of “benign” multiple sclerosis at 20 years AL Sayao, V Devonshire, H Tremlett Neurology 68 (7), 496-500, 2007 | 214 | 2007 |
Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada E Kingwell, M Van der Kop, Y Zhao, A Shirani, F Zhu, J Oger, H Tremlett Journal of Neurology, Neurosurgery & Psychiatry 83 (1), 61-66, 2012 | 205 | 2012 |
Monthly ambient sunlight, infections and relapse rates in multiple sclerosis H Tremlett, IAF Van Der Mei, F Pittas, L Blizzard, G Paley, D Mesaros, ... Neuroepidemiology 31 (4), 271-279, 2008 | 200 | 2008 |
Multiple sclerosis progression: time for a new mechanism-driven framework T Kuhlmann, M Moccia, T Coetzee, JA Cohen, J Correale, J Graves, ... The Lancet Neurology 22 (1), 78-88, 2023 | 198 | 2023 |
Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review E Lu, BW Wang, C Guimond, A Synnes, D Sadovnick, H Tremlett Neurology 79 (11), 1130-1135, 2012 | 190 | 2012 |